longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Jazz Pharma

JAZZ

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 16.81, within the reasonable range, cheaper than 47.25% of the time in the past 3 years, and the industry ranks 30/257, the industry Median -1.27.

16.81xP/E
$243.59Stock price
$14.49Earnings per share
16.81xP/E
Stock price$243.59Earnings per share$14.49

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
16.45x
Typical range
-20.39x–20.77x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
NVOUSNovo Nordisk AS
10.19x6.46%$184.48B
BMYUSBristol Myers Squibb
14.00x62.25%$129.92B
GSKUSGSK
15.90x6.56%$102.48B
UCBJYUSUCB S.A.
17.68x--$45.03B
HLNUSHaleon
18.70x2.92%$40.56B
OTSKYUSOtsuka Pharmaceutical
14.16x--$36.65B
DSNKYUSDaiichi Sankyo
19.65x--$33.00B
ZTSUSZoetis
11.44x6.81%$30.17B
ALPMYUSAstellas Pharma
11.36x--$26.48B
JAZZUSJazz Pharma
16.81x349.11%$15.81B
OPHLYUSOno Pharmaceutical
14.21x--$6.92B
INDVUSIndivior Pharmaceuticals
11.39x126.83%$4.05B
OGNUSOrganon
17.18x211.11%$3.59B
SNPHYUSSanten Pharmaceutical
13.91x--$3.44B
HRMYUSHarmony Biosciences
13.56x45.48%$2.46B
PBHUSPrestige Brands
12.91x7.48%$2.22B
GTBIFUSGreen Thumb Industries Inc.
13.51x--$1.71B
ANIPUSANI Pharma
16.60x49.55%$1.65B
PAHCUSPhibro Animal Health
14.37x26.75%$1.43B
OMERUSOmeros
10.06x1,880.00%$1.26B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.